◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2257

Sirnaomics Ltd. (2257) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

Sirnaomics Ltd. (2257) operates in the Biotechnology industry and is headquartered in Germantown, United States with about 37 employees. Its market capitalization is roughly $435 million. In the fiscal year ended 2025-12-31, 2257 reported $0M in revenue and ($14M) in net income.

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People's Republic of China.

Interactive charts & full statements →

2257 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$2M$0M$0M
Gross Profit$0M$1M$0M
Operating Income (EBIT)($15M)($36M)($77M)($91M)
Net Income($14M)($51M)($79M)($88M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2257 Free Cash Flow History

2257 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$21M$28M$76M$164M
Total Liabilities$45M$44M$51M$52M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2257 viewer.

Other Companies in Biotechnology

← 2256All “0-9” companies2258 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.